The impact of low-volume hydration on kidney function in low-dose cisplatin therapy for biliary tract cancer: a multicentre retrospective cohort study

). Of 239 patients, 109 LV and 97 HV patients were analysed. Primary endpoint was acute kidney injury (AKI) incidence. Propensity score weighting was applied to adjust for confounders. Post-adjustment AKI incidence was 4.7% (LV) vs. 10.1% (HV), confirming non-inferiority (risk difference upper 95% CI: 0.002, margin <0.05). No significant differences were observed in serum creatinine or creatinine clearance trajectories. In conclusion, low-volume hydration was non-inferior to high-volume hydration for AKI risk in low-dose cisplatin therapy. These findings support tailoring hydration to reduce patient burden without compromising safety.